摘要
A novel bispecific T-cell engager(BiTE)has been developed as an efficient immunotherapeutic molecule specifically bringing the T-cell and the tumor target together for enhanced immunotherapy.The general BiTE construct consists of two single-chain variable antibody fragments(scFvs)targeting a tumor-associated antigen(TAA)and a T-cell marker in tandem.The binding of BiTEs to tumor antigens induces immediate T-cells’cytotoxicity against tumor cells without involving any typical costimulatory signals,specific TCR and MHC recognition.
基金
This research was partly funded by grants from the International(Regional)Cooperation and Exchange Program of National Natural Science Foundation of China(No.82220108003)
the Guangxi Key Research and Development Program(No.GuiKe-AB21196024)
the National Key Research and Development Program of China(No.2019YFE0117300)
the fund for Less Developed Regions of the National Natural Science Foundation of China(No.82260478)
the Specific Research Project of Guangxi for Research Bases and Talents(No.GuiKe-AD20238062)
the Guangxi Key Laboratory of Nanobody Research(No.21-220-16).
